Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Equity Ratio (2016 - 2026)

Anika Therapeutics has reported Equity Ratio over the past 17 years, most recently at 0.75 for Q1 2026.

  • Quarterly Equity Ratio fell 4.13% to 0.75 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.75 through Mar 2026, down 4.13% year-over-year, with the annual reading at 0.75 for FY2025, 0.73% down from the prior year.
  • Equity Ratio was 0.75 for Q1 2026 at Anika Therapeutics, down from 0.75 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.84 in Q1 2022 and troughed at 0.75 in Q1 2026.
  • The 5-year median for Equity Ratio is 0.79 (2024), against an average of 0.79.
  • Year-over-year, Equity Ratio increased 9.34% in 2022 and then dropped 5.7% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.82 in 2022, then decreased by 4.11% to 0.78 in 2023, then decreased by 3.16% to 0.76 in 2024, then decreased by 0.73% to 0.75 in 2025, then dropped by 1.0% to 0.75 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Equity Ratio are 0.75 (Q1 2026), 0.75 (Q4 2025), and 0.77 (Q3 2025).